skip to Main Content

Novel Combination Therapeutic Approach Could Increase Survival of Pancreatic Cancer Patients

Newsfeed image, light gray text on dark gray background
Pancreatic cancer currently is the third-leading cause of cancer death in the US. Depending on the stage, the standard course of treatment is surgery, radiation and chemotherapy. While these treatments can help extend patient survival, pancreatic cancer often progresses, underscoring the need for additional novel treatment strategies.

Pancreatic cancer is also associated with the dysregulation of certain epigenetic regulators, such as bromodomain and extraterminal motif (BET) proteins. These proteins read histone acetylation marks on chromatin while also facilitating the transcription of oncogenes that are essential for cancer cell survival and proliferation. Read more . . . 


Back To Top